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SUMMARY
Medulloblastoma (MB) is the most common malignant brain tumor in children. Patients whose
tumors exhibit overexpression or amplification of the MYC oncogene (c-MYC) usually have an
extremely poor prognosis, but there are no animal models of this subtype of the disease. Here we
show that cerebellar stem cells expressing Myc and mutant Trp53 (p53) generate aggressive
tumors following orthotopic transplantation. These tumors consist of large, pleiomorphic cells and
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resemble human MYC-driven MB at a molecular level. Notably, antagonists of PI3K/mTOR
signaling, but not Hedgehog signaling, inhibit growth of tumor cells. These findings suggest that
cerebellar stem cells can give rise to MYC-driven MB, and identify a novel model that can be used
to test therapies for this devastating disease.
INTRODUCTION
MB is a highly malignant tumor of the cerebellum that occurs most frequently in children
between 5 and 10 years of age (Polkinghorn and Tarbell, 2007). Current treatment for MB
includes resection of the tumor followed by radiation and high-dose chemotherapy.
Although this has resulted in significant increases in survival, ~1/3 of MB patients still die
from their disease. Moreover, survivors often suffer severe side effects, including dramatic
losses in cognitive function, endocrine disorders and increased susceptibility to secondary
tumors (Palmer et al., 2007; Stavrou et al., 2001). Thus, more effective and less toxic
therapies for MB are desperately needed.
Traditionally, MB has been classified based on histological characteristics. In this context,
tumors with large cell-anaplastic (LCA) features are associated with a much poorer
prognosis than classic or nodular/desmoplastic tumors (Eberhart and Burger, 2003; Leonard
et al., 2001). Recently, several groups (Cho et al., 2010; Kool et al., 2008; Northcott et al.,
2010; Remke et al., 2011; Thompson et al., 2006) have performed gene expression profiling
and DNA copy number analysis of MB, and have identified at least 4 major subtypes of the
disease: WNT, Sonic hedgehog (SHH), Group C and Group D. These molecular subtypes
have distinct characteristics in terms of gene expression, mutational profiles, epidemiology
and prognosis. Among molecular subtypes, tumors associated with WNT pathway activation
have the most favorable outcome, whereas those that exhibit overexpression or amplification
of MYC and lack WNT pathway activation (termed Group C (Northcott et al., 2010) or
Group c1 (Cho et al., 2010), herein referred to as MYC-driven MB) have the worst
prognosis. Although LCA histology can be found in all molecular subtypes of the disease, it
is more common in MYC-driven tumors. Patients with MYC-driven MB are also more
likely to exhibit metastatic disease at the time of diagnosis, to undergo recurrence, and to die
of their disease (Northcott et al., 2010). More effective treatments for MYC-driven MB
depend on a deeper understanding of the biology of the disease.
The fact that ectopic expression of MYC can cause MB cell lines to adopt an anaplastic
phenotype (Stearns et al., 2006), and the fact that high MYC levels are associated with poor
clinical outcome (Cho et al., 2010; Grotzer et al., 2001) suggest that MYC might play a key
role in the biology of MB. But while the association between MYC and poor prognosis is
well established, it remains unclear whether the gene is involved in tumor initiation,
maintenance or progression. Likewise, MYC-driven tumors frequently exhibit loss of one
allele of the TP53 tumor suppressor (in context of isochromosome 17q) (Northcott et al.,
2010; Pfister et al., 2009), and LCA tumors have been reported to express high levels of p53
protein, an indicator of dysregulation of the TP53 pathway (Eberhart et al., 2005; Frank et
al., 2004). However, it is not clear if alterations in TP53 represent causal events.
Animal models of brain tumors can be generated by targeting expression of oncogenes to
neural progenitors or stem cells. Recent studies suggest that different populations of
progenitors may be susceptible to transformation by distinct signaling pathways (Gilbertson
and Ellison, 2008). For example, mutations in the SHH pathway promote transformation of
granule neuron precursors (GNPs) in the external germinal layer of the cerebellum (Schuller
et al., 2008; Yang et al., 2008), whereas dysregulation of WNT signaling causes
transformation of progenitors in the lower rhombic lip and embryonic dorsal brainstem
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(Gibson et al., 2010). We recently identified a population of stem cells in the white matter of
the postnatal cerebellum (Lee et al., 2005), and hypothesized that they might give rise to
some types of MB. To test this hypothesis and to address the functional importance of MYC
and TP53 in MB, we examined the effects of overexpressing Myc and disrupting p53
function in these cells.
RESULTS
Myc promotes proliferation of cerebellar stem cells in vitro
Stem cells can be isolated from the postnatal cerebellum based on expression of Prominin1
(CD133) and lack of neuronal and glial lineage markers (Prom1+Lin−). To investigate the
effects of Myc on these cells, we infected them with control retroviruses or viruses encoding
a stabilized form of Myc (MycT58A) (Chang et al., 2000) and measured their proliferation.
As shown in Figure 1A, Myc-infected cells showed a 2.5 fold increase in proliferation
compared to cells infected with control viruses. To examine the effects of Myc on self-
renewal, infected Prom1+ Lin− cells were cultured at low density (2000 cell/ml) in the
presence of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) to
promote neurosphere formation. As shown in Figures 1B–D, the number of neurospheres in
Myc-infected cultures was 9-fold higher than that in control cultures. To determine whether
the effects of Myc persisted in longer-term cultures, neurospheres were dissociated into
single-cell suspensions and re-plated every 7 days. Over the course of 5 weeks, Myc-infected
cultures exhibited a 1000-fold increase in cell number, compared to a 2-fold increase in
control cultures (Figure S1). These data indicate that overexpression of Myc in cerebellar
stem cells promotes short-term proliferation as well as long-term self-renewal in vitro.
Myc-expressing stem cells form transient hyperplastic lesions in vivo
In light of the above results, we investigated whether Myc-expressing cells could give rise to
tumors in vivo. We stereotaxically implanted control (GFP virus-infected) or Myc-infected
stem cells into the cerebellum of immunocompromised (NOD-SCID-IL2RGammanull, or
NSG) mice and examined cerebella of recipients 2–3 weeks later. As shown in Figures 2A–
B, in animals that had received control cells, few infected cells (marked by GFP) could be
detected, and only a small proportion of these were proliferating (based on Ki67 staining). In
contrast, in animals transplanted with Myc-expressing cells, large masses of infected cells
could be detected, and the majority of these were proliferating (Figures 2C–F). These results
suggest that Myc-infected cells can undergo persistent proliferation in vivo.
To determine whether Myc-infected cells can continue to grow and give rise to tumors, we
sacrificed animals (n=5) four weeks after transplantation. Surprisingly, at this stage, few
transplanted cells could be detected in the cerebellum of mice that had received either
control or Myc infected cells. Consistent with this, we followed a cohort of mice (n=6)
transplanted with Myc-infected cells for 6 months, and found that none of them developed
symptoms during this period (data not shown). This suggested that Myc can drive
proliferation of stem cells, but is not sufficient to promote tumor growth.
The fact that Myc infected cells formed large masses 2 weeks after transplantation but were
undetectable 4 weeks after transplantation raised the question of what happened to these
cells. Since Myc can induce apoptosis as well as proliferation (Pelengaris et al., 2000) we
examined cerebella from recipients of control and Myc-infected cells for evidence of
apoptosis by staining with anti-cleaved caspase 3 (CC3). Few control virus-infected cells
were labeled with anti-CC3 (although some staining was seen around the transplant site)
whereas Myc-infected cells exhibited a significant amount of CC3 staining (Figures 2G–H),
Pei et al. Page 3













suggesting that they were undergoing apoptosis in situ. These data suggest that Myc
promotes proliferation as well as apoptosis of cerebellar stem cells.
Mutant p53 synergizes with Myc to promote tumor formation
MYC-induced apoptosis is frequently dependent on TP53 (Hermeking and Eick, 1994). To
test whether inactivation of p53 could inhibit Myc-induced cell death in cerebellar stem
cells, we measured apoptosis in cells infected with control (GFP), Myc, DNp53 (Bowman et
al., 1996) or Myc + DNp53 viruses. As shown in Figure S2A–D, cells infected with Myc
viruses alone exhibited a marked increase in apoptosis compared to cells infected with
control viruses (Figures S2A–B), but DNp53 completely abolished the pro-apoptotic effects
of Myc (Figures S2C–D). These results suggest that Myc mediated apoptosis of stem cells
can be blocked by inhibition of p53 function.
The above findings raised the possibility that cells overexpressing Myc and DNp53 might be
able to give rise to tumors. To test this, we co-infected stem cells with viruses encoding
these genes and implanted them into the cerebellum of NSG mice. Animals transplanted
with cells co-expressing the two genes developed highly aggressive tumors and had to be
sacrificed between 6–12 weeks (Figures 3A–B). These experiments were performed using
the T58A mutant of Myc. Notably, stem cells infected with WT Myc + DNp53 also gave rise
to tumors, albeit with reduced penetrance (33%) and longer latency (15–20 weeks). These
studies suggest that mutant p53 can cooperate with Myc to promote transformation of
cerebellar stem cells.
We characterized tumors arising from stem cells infected with Myc and DNp53 (MP tumors)
using tumors from Ptch1 mutant mice (a model for SHH-associated MB) for comparison
(Figures 3C–H). Whereas Ptch1+/− tumor cells were not much bigger than normal granule
neurons (~ 5 μm, compare arrow to arrowhead in Figure 3H), cells from MP tumors were
approximately 5 times bigger (~ 25 μm, compare vertical and horizontal arrows in Figure
3E). In addition, MP tumors exhibited prominent necrosis (asterisk in Figure 3C) and
nuclear molding (arrows in Figures 3D–E), whereas Ptch1+/− tumors rarely displayed these
features (Figures 3G–H). Importantly, the histological features of murine MP tumors
resembled those of human LCA (Group C) MB (Figure S3). Together these data suggested
that MP tumors are distinct from SHH-driven tumors and histologically resemble human
LCA MB.
Immunohistochemical characterization of MP tumors demonstrated that they have a high
proliferative index and often express the stem cell/progenitor marker Nestin (Figures 4A–
4C). Tumor cells that did exhibit differentiation predominantly expressed the early neuronal
lineage marker Tuj1 (class III beta-tubulin, Figure 4D). Only rare tumor cells expressed the
mature neuronal marker synaptophysin (not shown) or the astrocytic marker GFAP (Figure
4E), consistent with the notion that MP tumors are poorly differentiated. Tumors also did
not express O4, NG2, PDGFRa or SOX10, markers associated with oligodendrogliomas
(data not shown). Finally, tumor cells expressed significant amounts of the chromatin
remodeling protein BAF47 (also known as Smarcb1, Snf5 or Ini1), which is commonly lost
in atypical teratoid/rhabdoid tumor (AT/RT), suggesting that we were not modeling this type
of tumor (Figure 4F). Based on these observations, we concluded that MP tumors are highly
proliferative and poorly differentiated, features consistent with LCA MB.
MP tumors can be generated from granule neuron precursors
Previous studies have suggested that SHH-associated MB can be initiated in GNPs or neural
stem cells (Schuller et al., 2008; Yang et al., 2008), We therefore determined whether GNPs
could also be transformed by Myc and DNp53. To test this, we FACS-sorted GFP+ cells
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(GNPs) from neonatal Math1-GFP transgenic mice (Lee et al., 2005; Lumpkin et al., 2003)
(Figures S4A, B), infected these cells with Myc and DNp53 viruses, and then transplanted
them into the cerebellum of NSG mice. We found that 7 out of 22 recipients developed
tumors, with a latency of 108 days (Figure S4D, E, F). Interestingly, although the cells were
GFP+ prior to transplantation (Figure S4B), the tumors that developed from them were no
longer GFP+ when analyzed by microscopy or flow cytometry (Figures S4C, E), suggesting
that they had lost a key marker of the granule lineage during the course of transformation.
These studies demonstrate that both stem cells and GNPs can give rise to MYC-driven
tumors.
Myc is required to maintain MP tumor growth
In many tumors driven by MYC, shutting off the expression of MYC results in tumor
regression (Jain et al., 2002; Soucek et al., 2008). To determine whether MP tumors
continue to depend on Myc once they are established, we infected stem cells with viruses
encoding a tetracycline–inducible form of Myc along with DNp53-IRES-Luciferase, and
transplanted these cells into the cerebellum of NSG mice. Mice were fed doxycycline
(DOX)-containing food until they developed tumors (3–4 weeks after transplantation).
Tumors were removed, dissociated and re-transplanted into cerebella of naïve NSG mice.
Secondary recipients were separated into 3 groups: Group 1 (n=14) was maintained on
DOX-containing food; Group 2 (n=14) was fed DOX-containing food for 1 week, then
switched to normal food; and Group 3 (n=12) was fed food without DOX (Figure 5A).
Animals in all groups developed bioluminescent signals (from the luciferase encoded by the
DNp53 virus), indicating the presence of transplanted tumor cells. Group 1 animals showed
a rapid and dramatic increase in bioluminescence (Figure 5B, top graph), and by 3–4 weeks
after transplantation, all mice had developed symptoms and had to be sacrificed (Figure 5F).
Analysis of brains from these mice revealed large tumors in every animal (Figure 5C). In
contrast, bioluminescence in Group 2 and 3 mice decayed in the absence of DOX (Figure
5B, bottom two graphs). Moreover, no tumors could be detected in these animals 3 weeks
after transplantation (Figures 5D–E), and animals remained asymptomatic at 6 weeks
(Figure 5F). Together these data suggest that Myc is not only necessary for tumor initiation
but is also required to maintain growth of MP tumors.
MP tumors resemble human MYC-driven MB
Our histological analysis indicated that MP tumors resemble human LCA MB. Since LCA
histology is more common in MYC-driven tumors (Cho et al., 2010; Northcott et al., 2010),
this supported the notion that MP tumors might represent a model for human MYC-driven
MB. To test whether MP tumors resembled human MYC-driven MB at a molecular level,
we performed gene expression analysis of MP tumors and compared the resulting gene
expression profiles with profiles of the 4 subtypes of human MB (WNT, SHH, Group C and
Group D) defined by (Northcott et al., 2010). In this classification scheme, Group C tumors,
which are associated with the poorest prognosis, frequently exhibit amplification or
overexpression of MYC (Northcott et al., 2010). Using genes differentially expressed in
each subgroup and previously published methods (Bild et al., 2006), we identified 4 sets of
genes (“subgroup signatures”) whose expression accurately predicted the subgroup of the
human MB samples (see Human Tumor Analysis Supplement).
Human MB subgroup signatures were then applied to gene expression data from murine MP
and Ptch1 mutant tumors, with each tumor receiving a subgroup signature score representing
its similarity to each subgroup of human MB. As shown in Figure 6A and Table S1, murine
Ptch1 tumors most closely resembled human SHH associated tumors, with one exception,
which possessed a profile consistent with both the WNT and SHH groups. In contrast, MP
tumors were most similar to Group C/D tumors, with the exception of a tumor that
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resembled both the WNT and Group C/D signatures. To validate these findings, we
compared data from murine tumors to expression profiles from a distinct set of human MB
samples (Cho et al., 2010). Utilizing a subclass mapping algorithm (Hoshida et al., 2007) we
generated a similarity metric between MP tumors and the MB subgroups defined in Cho et
al. As shown in Figure S5, this analysis revealed a high degree of similarity between MP
tumors and the ‘c1’ subtype of human MB, which is characterized by copy number gains of
c-MYC and gene expression signatures indicative of robust MYC transcriptional activity
(Cho et al. 2010).
Finally, we stained an independent set of MP and Ptch1 tumors with antibodies that have
been found to mark each of the 4 human MB subgroups (Northcott et al., 2010). Murine
Ptch1 mutant tumors expressed high levels of the SHH subgroup marker SFRP1 (Figure 6B)
and lacked expression of the WNT subgroup marker nuclear CTNNB1 (not shown), the
Group C marker NPR3 (Figure 6C) and the Group D marker KCNA1 (Figure 6D). In
contrast, MP tumors exhibited high levels of NPR3 (Figure 6F) and lacked expression of the
other markers (Figures 6E, G and data not shown). Together, these data suggested that MP
tumors resemble human Group C (MYC-driven) MB.
Gene expression profile of MP tumors
We compared the gene expression profiles of MP tumors to those of freshly isolated
cerebellar stem cells and tumors from Ptch1 mutant mice. Using principal component
analysis – an unsupervised approach designed to group samples based on their similarity in
gene expression – we determined that MP tumors generated by infection of Prom1+Lin−
stem cells and those generated by infection of Prom1+ cells were indistinguishable based
upon global RNA expression (Figure 7A). Both of these tumor types were distinct from
normal (uninfected) cerebellar stem cells and from Ptch1 mutant tumors. Hierarchical
clustering (Figure 7B) confirmed the similarity between MP tumors generated from
Prom1+Lin− and Prom1+ cells as well as the differences between these tumors, Ptch1
tumors and normal stem cells. Focusing on changes in gene expression of 3-fold and higher
(p-value with FDR correction < 0.0001), we identified 1228 genes (1465 probe sets) that
were differentially expressed between MP tumors and Ptch1 tumors (Table S2), and 812
genes (955 probe sets) differentially expressed between MP tumors and normal stem cells
(Table S3).
To learn about the functional significance of these genes, we analyzed them using Gene Set
Enrichment Analysis (GSEA) (Subramanian et al., 2005) and using NextBio software
(Kupershmidt et al., 2010) (see Figure 7 and Tables S4–S5). Several important correlations
emerged from this analysis. First, we noted that genes expressed at high levels in MP tumors
were similar to those found to be targets of MYC in other studies (Figure 7C, Tables S4–
S5). Another set of differentially expressed genes, which exhibited decreased expression in
MP tumors, were targets of forkhead transcription factors (e.g. Foxo1, Figure 7D). This is
notable because FOXO proteins often inhibit expression of MYC targets, induce expression
of MYC antagonists, and suppress MYC-induced transformation (Bouchard et al., 2007;
Bouchard et al., 2004; Delpuech et al., 2007). We also noted a marked similarity between
genes expressed in MP tumors and those enriched in embryonic stem (ES) cells and induced
pluripotent stem (iPS) cells, including those induced by Oct4 and Klf4 (i.e., in the absence of
exogenous Myc) (Figure 7F). These genes were enriched in MP tumors compared to Ptch1
tumors, consistent with the fact that the former are derived from stem cells and the latter
originate from lineage-restricted neuronal progenitors. However, they were also enriched in
MP tumors compared to cerebellar stem cells, suggesting that MP tumors have adopted a
more primitive differentiation state than the cells from which they were derived. In support
of this notion, MP tumors showed decreased expression of genes associated with neuronal
lineage commitment and differentiation (Figure 7E). Finally, our analysis revealed
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significant enrichment of a PI3K signaling gene set as well as a set of genes down-regulated
by rapamycin in another cancer cell line (Tables S4–5). Notably, analysis of human MYC-
driven (Group c1) tumors using Connectivity Map (CMAP) – an algorithm that screens a
given gene expression signature against a compendium of drug-induced gene expression
signatures (Lamb et al., 2006) – suggested that genes regulated by PI3K and mTOR
inhibitors are also enriched in these tumors (Table S6). These observations, and the fact that
MP tumors have decreased expression of Foxo targets, which are negatively regulated by the
PI3K pathway, suggested that this pathway might play an important role in tumor growth.
MP tumors are sensitive to inhibitors of PI3 Kinase and mTOR
To determine whether MP tumors were dependent on PI3K/mTOR signaling, we first tested
the effects of PI3K/mTOR inhibitors on tumor cell growth in vitro (Figure 8A). MP tumors
showed complete growth inhibition in the presence of 1–5 μM BEZ-235 (an antagonist of
both PI3K and mTOR) and 5 μM BKM-120 (an antagonist of PI3K), and partial inhibition
in the presence of lower concentrations of these compounds. The mTOR antagonist
RAD-001 also inhibited growth, albeit incompletely, at concentrations of 0.2 – 5 μM.
Consistent with their continued dependency on Myc, tumor cells were dramatically inhibited
by 10058-F4, a small molecule that interferes with Myc-Max dimerization (Huang et al.,
2006). In contrast, we found that MP tumor cells showed no growth inhibition in response to
the SHH antagonist cyclopamine.
To determine whether BEZ-235 and BKM-120 could also affect long-term tumor cell
growth, we cultured MP tumor cells for 3, 7 or 14 days in the presence of these inhibitors,
and counted cell number at each time point. We found that all three doses of BEZ-235
inhibited cell growth whereas only the highest concentration of BKM-120 (5 μM) was able
to cause growth inhibition (Figure 7B). Similar results were observed when we used
neurosphere assays to measure tumor cell clonogenicity (Figure S6).
To confirm that these compounds were acting on the PI3K/mTOR pathway, we performed
western blotting to analyze phosphorylation of critical proteins in the pathway. As shown in
Figure 8C, MP tumor cells showed substantial amounts of phospho-AKT and phospho-S6 in
the absence of inhibitors (DMSO lanes). Treatment with BEZ-235 or BKM-120 inhibited
phosphorylation of both AKT and S6. In contrast, RAD-001 inhibited S6 phosphorylation
but did not affect phospho-AKT. The fact that BEZ-235 and BKM-120 were more potent
inhibitors of tumor cell proliferation than RAD-001 (Figures 8A–B) suggested that blocking
activity of PI3K, or both PI3K and mTOR, might be required for effective tumor inhibition.
To determine whether inhibition of PI3K/mTOR signaling could also inhibit growth of MP
tumors in vivo, we isolated MP tumor cells and transplanted them into naïve NSG mice.
After 7 days, we began treating animals with BKM-120 once daily until clinical signs of
tumor formation were observed. Animals treated with BKM-120 survived significantly
longer than controls (median survival = 35 vs. 25 days) (Figure 8D). These results suggest
that inhibitors of PI3K/mTOR signaling might be useful for treatment of MYC-driven MB.
DISCUSSION
MYC-driven MB is a highly malignant pediatric brain tumor that is often resistant to
conventional radiation and chemotherapy. More effective approaches to treat this disease are
critical, and these can be facilitated by the development of robust animal models. The fact
that a subset of human MBs exhibit amplification or overexpression of MYC prompted us to
develop a mouse model that can be used to investigate the biology of and test therapies for
MYC-driven MB.
Pei et al. Page 7













Cooperation between Myc and mutant p53
Our observation that Myc induces proliferation of cerebellar stem cells is consistent with
previous reports showing mitogenic effects of Myc in normal and malignant stem cells
(Nagao et al., 2008; Wang et al., 2008). However, while Myc can promote proliferation of
cerebellar stem cells in vitro, it cannot, on its own, sustain long-term growth in vivo. Our
studies suggest that this is due to Myc-induced apoptosis, but this raises the question: why
are these cells more sensitive to apoptosis in vivo? One reason may be that in vitro they are
maintained under conditions that favor neurosphere formation, including high levels of EGF
and bFGF. In the presence of such growth factors, the proliferative response to Myc often
dominates over the apoptotic response (Harrington et al., 1994). It is also possible that the in
vivo microenvironment contains factors that actively inhibit growth or survival of
transplanted stem cells. In either case, it is clear that the potent mitogenic effects of Myc are
insufficient to drive transformation.
Whereas stem cells expressing Myc alone do not form tumors, cells expressing Myc and
mutant p53 are highly tumorigenic. Dysregulation of the TP53 pathway, as evidenced by
elevated expression of p53 protein, is a common feature of human LCA MB (Eberhart et al.,
2005; Frank et al., 2004; Tabori et al., 2010). Moreover, human MYC-driven MBs often
exhibit isochromosome 17q, which is associated with monoallelic loss of TP53 (Cho et al.,
2010; Northcott et al., 2010). Thus, loss of p53 function could synergize with MYC
overexpression in human MB as well. The ability of mutant TP53 to cooperate with MYC
has been observed in many other cancers (Elson et al., 1995; Hemann et al., 2005), but the
mechanisms underlying this cooperation are not fully understood. In our system, Myc-
induced apoptosis is dependent on endogenous p53, and DNp53 acts, at least in part, by
blocking this function. (Hermeking and Eick, 1994). However, loss of p53 function has also
been reported to increase neural stem cell self-renewal and to promote pluripotency
(Kawamura et al., 2009; Meletis et al., 2006; Zheng et al., 2008), both of which could
certainly contribute to transformation. Moreover, loss of p53 function promotes genomic
instability (Hanel and Moll, 2011), which could result in additional mutations that promote
tumor formation. Which of these functions of p53 are most critical in our tumors is the
subject of ongoing studies.
Our observation that stem cells can be transformed by the combination of Myc and DNp53 –
but not by either gene alone – suggests that these genes are both required for tumor
initiation. But whether initiating oncogenes continue to be required once tumors are formed
is unclear. Previous studies have demonstrated that in many types of cancer, tumors become
addicted to expression of the oncogene and undergo regression when expression is shut off
(Jain et al., 2002; Soucek et al., 2008). However, there have been reports of tumors that
continue to grow even when Myc is silenced (Boxer et al., 2004). Our results suggest that
continued expression of Myc is required for maintenance of MP tumor growth. If similar
findings hold true for human MYC-driven MB, it would suggest that targeting MYC itself
might be an effective approach to therapy.
MP tumors as a model for human MB
The tumors that are induced by Myc and DNp53 resemble human LCA and MYC-driven
MB. Interestingly, two other groups have recently described animal models of LCA MB.
Deletion of Rb and p53 in neural progenitors results in tumors that exhibit amplification of
MycN and resemble LCA MB (Shakhova et al., 2006). Likewise, mice in which MycN is
overexpressed in Glt1+ progenitors develop either classic or LCA MB (Swartling et al.,
2010). While each of these tumors exhibits large cell-anaplastic histology, it is important to
note that they may not all represent the same subtype of MB. We have previously reported
that LCA histology can occur in all molecular subgroups of MB, including WNT, SHH,
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Group C and Group D tumors (Northcott et al., 2010). However, MBs that overexpress
MYCN are largely distinct from those that overexpress MYC. Thus, the models described
by these groups may correspond to human MYCN-associated MB, whereas MP tumors may
represent human MYC-driven (Group C) MB. Interestingly, tumors of a recently developed
MB model in which Rb and p53 were deleted in postnatal cerebellar stem cells did not
overexpress MycN and, like our tumors, expressed high levels of NSC markers (Sutter et al.,
2010). It will be interesting to compare these models at a molecular level to determine the
similarities and differences between them.
Cellular origins of Myc associated tumors
Previous studies have shown that activation of the SHH pathway in GNPs results in MB
with 100% penetrance (Schuller et al., 2008; Yang et al., 2008). Moreover, activation of the
SHH pathway in stem cells within the cerebellar ventricular zone (VZ) results in expansion
of the VZ, but cells do not become transformed until they commit to the granule lineage
(Schuller et al., 2008; Yang et al., 2008). These studies suggest that lineage restriction is a
critical determinant of susceptibility to transformation by SHH signaling. The current
studies suggest that Myc + DNp53 can also cause transformation of both stem cells and
GNPs. However, once transformed, the stem cells do not appear to undergo lineage
commitment; indeed, their gene expression profile suggests that Myc/DNp53-transformed
cells are even more immature or undifferentiated than normal neural stem cells. Moreover,
when GNPs are infected with Myc and DNp53 viruses, they lose expression of GNP lineage
markers during the course of transformation. These results demonstrate that stem cells and
GNPs can both serve as cells of origin for MYC-driven MB, and suggest that lineage
commitment is not required for (and in fact, may be incompatible with) transformation.
Molecular phenotype of MP tumors
In addition to highlighting the similarities between MP tumors and human MYC-driven MB,
our gene expression analysis also revealed that genes overexpressed in MP tumors are
similar to those expressed by embryonic and pluripotent stem cells. The association between
pluripotency and cancer has been noted in a number of other systems. For example, in breast
cancer, glioblastoma and bladder carcinoma, an ES-like signature is associated with
aggressive, poorly differentiated tumors and is a predictor of poor prognosis (Ben-Porath et
al., 2008). Likewise, a pluripotency signature is associated with transformation of follicular
lymphoma to diffuse large B-cell lymphoma (Gentles et al., 2009). There has been some
debate about whether this signature reflects true acquisition of pluripotent characteristics or
simply activation of a MYC-driven gene expression profile (Kim et al., 2010). In the case of
MP tumors, there is no question that a Myc-driven transcriptional program is active and
plays a significant role in driving tumor growth. However, it is worth noting that the genes
identified as differentially expressed in MP tumors also resemble those associated with
pluripotency induced by Oct4 and Klf4 suggesting that the pluripotency program in our cells
is not purely a consequence of Myc overexpression. It is also notable that MP tumors
express lower levels of neural differentiation markers compared to not only Ptch1 tumors
(which consist of neuronal progenitor-like cells) but also normal neural stem cells from
which they were derived. These findings suggest that transformation of NSCs may involve
de-differentiation to a more pluripotent state.
Among the most important results of our analysis was the observation that MP tumors have
increased expression of genes associated with PI3K/AKT/mTOR signaling and decreased
expression of Foxo target genes. FOXO proteins have been shown to inhibit expression of
MYC targets (Bouchard et al., 2004), and MYC-induced transformation requires
inactivation of FOXO proteins (Bouchard et al., 2007). Importantly, AKT has been shown to
phosphorylate FOXO proteins and thereby prevent them from entering the nucleus
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(Bouchard et al., 2004). Although the cause of PI3K pathway activation in MP tumors is
unclear, it seems likely that this activation interferes with Foxo activity and thereby
synergizes with Myc overexpression to promote transformation. PI3K signaling has also
been shown to increase Myc protein stability (Kumar et al., 2006) and to enhance Myc
function by promoting degradation of its antagonist Mad1 (Zhu et al., 2008). Thus, the PI3K
pathway may be a critical regulator of transformation in MP tumors.
In light of the above findings, we hypothesized that inhibition of PI3K signaling might block
growth of MP tumors. Whereas inhibition of the SHH pathway had little effect on growth of
these cells, treatment with the PI3K/mTOR inhibitors BEZ-235 and BKM-120 had a potent
inhibitory effect on tumor growth both in vitro and in vivo. Several studies have documented
activation of PI3K signaling in human MB (Castellino et al., 2010; Hartmann et al., 2006).
In particular, genomic analysis suggests that MYC-driven MBs frequently exhibit loss of
chromosome 10q (where PTEN is located) (Northcott et al., 2010). Consistent with this, our
CMAP analysis (Table S6) suggests that MYC-driven tumors have elevated expression of
genes that are regulated by PI3K and mTOR inhibitors. Together, these findings suggest that
targeting the PI3K/mTOR pathway may be useful for treatment of human MB. Further
studies using this novel model of MYC-driven MB will shed light on the biology of this
disease and open up new targets for therapy.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6J mice used as a source of stem cells and immunocompromised (NOD-scid
IL2Rgammanull or NSG) mice used for transplantation were purchased from Jackson Labs
(Bar Harbor, ME). Mice were maintained in the Cancer Center Isolation Facility at Duke
University and in the Animal Facility at Sanford-Burnham. All experiments were performed
in accordance with national guidelines and regulations, and with the approval of the animal
care and use committees at each institution.
Orthotopic transplantation and tumor formation
Before transplantation, cerebellar stem cells (Prom1+Lin− cells) or GNPs (GFP+ cells
FACS-sorted from Math1-GFP transgenic mice) were infected with Myc and DNp53
retroviruses for 20 hr. 1×105 stem cells in Neurocult medium or 1 x 106 GNPs suspended in
Neurobasal medium were injected into the cerebellum of NSG mice (6–8 weeks old) using a
stereotaxic frame with a mouse adaptor (David Kopf Instruments), as described previously
(Yang et al., 2008). Animals were monitored weekly, and sacrificed when they showed
symptoms of MB.
To generate Tetracycline (Tet)-regulatable tumors, stem cells were infected with Tet-
inducible Myc lentivirus and DNp53 retrovirus. The Tet-inducible vector (pICUE-mycT58A)
consisted of a Tet-response element (TRE2) controlling expression of turbo red fluorescent
protein (tRFP) and Myc-T58A and a constitutive promoter controlling expression of the
reverse tetracycline transactivator (rtTA3) and eGFP (Meerbrey et al., 2011). Infected cells
were implanted into cerebella of NSG mice, and mice were manintained on DOX-containing
food. When mice became symptomatic, they were sacrificed and tumor cells were re-
transplanted into secondary NSG mice. These mice were separated into three groups. Group
1 (n= 14) was continually fed DOX-containing food, Group 2 (n=14) was fed DOX-food for
one week and normal food thereafter; and Group 3 (n=12) was not fed DOX-food at all.
Mice were subjected to bioluminescent imaging at 1, 2 and 3 weeks, and sacrificed at onset
of symptoms. At time of sacrifice, brains were removed and paraffin-embedded, sectioned
and stained with H&E.
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In vivo bioluminescent imaging
Mice were given intraperitoneal injections of 150 ng/g D-Luciferin (Caliper Life Sciences,
cat#12279) and anesthetized with 2.5% isoflurane. 7–8 min after injection, animals were
imaged using the Xenogen Spectrum (IVIS-200) imaging system.
In vivo inhibitor treatment
To study effects of the PI3-kinase antagonist BKM-120 on tumor growth in vivo, we re-
transplanted 500 MP tumor cells into cerebella of secondary NSG mice. 7 days after
transplantation, mice were randomly separated into two groups: Group 1 was given vehicle
(0.5% methyl-cellulose) and Group 2 was given 30 mg/kg BKM-120 by oral gavage once
daily until symptom onset. BKM-120 was dissolved in 0.5% methylcellulose and sonicated
using an ultrasonicator (Misonix) at an amplitude of 20 for 12 min. Survival was defined as
the time from transplantation until symptom onset.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Animal models are valuable for studying the origins and molecular mechanisms of
cancer, and can be used to develop and test new therapeutic strategies. Existing mouse
models of MB have been extremely useful for studying MB associated with Sonic
Hedgehog (SHH) pathway mutations. In contrast, no models have been developed to
study MYC-driven MB. Here we describe a mouse model of this tumor based on
transplantation of cerebellar stem cells expressing Myc and dominant-negative p53
(DNp53). These tumors resemble human MYC-driven MB at a histological and
molecular level, and can be inhibited by antagonists of the PI3K/mTOR pathway. This
model represents an important new tool for studying the biology and therapeutic
responsiveness of MYC-driven MB.
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• Myc promotes proliferation of cerebellar stem cells in vitro
• Mutant p cooperates with 53 Myc to transform stem cells into tumors
• Tumors resulting from Myc and mutant p53 resemble human MYC-driven MB
• Tumors are inhibited by PI3K/mTOR antagonists
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Figure 1. Myc promotes proliferation of cerebellar stem cells in vitro
(A), Prom1+Lin− cells sorted from cerebella of 5–7 day-old mice were infected with Myc-
IRES-GFP or control (GFP only) viruses for 48h, pulsed with tritiated thymidine (3H-Td)
and cultured overnight before being assayed for 3H-Td incorporation. Data represent means
of triplicate samples ± SEM. (B–D) Prom1+Lin− cells infected with Myc-IRES-GFP or
control viruses were cultured at low density in the presence of EGF and bFGF for 7 days.
Representative fields are shown in panels C and D (scale bars = 100 μm). The number of
GFP+ neurospheres is quantified in B; data represent means of triplicate samples ± SEM.
The infection efficiency was 80% with Myc-IRES-GFP and 90% with control retrovirus. See
also Figure S1.
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Figure 2. Myc-infected stem cells give rise to transient hyperplastic lesions following
transplantation
Prom1+Lin− cells were infected with Myc-IRES-GFP or control retroviruss for 20h and then
transplanted into the cerebellum of NSG mice. Hosts were sacrificed after 2.5 weeks. Frozen
sections from mice that received GFP-infected (A–B) or Myc infected cells (C–F) were
stained with anti-Ki67 antibodies (A–D) or H&E (E, F). Note the large mass of proliferating
(Ki67+) cells seen in animals that received Myc-infected cells (C, D). Box in E corresponds
to high-power field shown in F. Panels A–D and F, scale bars = 50 μm; panel E, scale bar =
100 μm. (G–H) Prom1+ cells were infected with Myc-ires-GFP or control-GFP viruses for
20h and then transplanted into the cerebellum of NSG hosts. Mice were sacrificed after 2
weeks. Frozen sections from mice that received control (G) or Myc infected cells (H) were
stained with antibodies specific for cleaved caspase-3 (CC3) to detect apoptotic cells. Scale
bars = 50 μm. See also Figure S2.
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Figure 3. Overexpression of Myc and inactivation of p53 transforms cerebellar stem cells into
tumors
Prom1+Lin− cells were infected with Myc + DNp53 retroviruses, Myc alone or DNp53 alone
for 20h, and transplanted into cerebella of NSG mice. Animals were sacrificed when they
developed symptoms. (A), Whole mount image of tumor, with GFP expression originating
from DNp53 retrovirus. (B) Survival curve of animals receiving 5 x104 cells infected with
Myc viruses (blue line), DNp53 viruses (green line) or Myc + DNp53 viruses (red line)
(median survival 48 days). (C–H) Sections of tumor tissue from animals transplanted with
cells expressing Myc and DNp53 (C–E) or from Ptch1 mutant mice (F–H) were stained with
hematoxylin and eosin. For C and F scale bars = 100 μm; for D, E, G and H, scale bars = 50
μm. Boxes in panels C and F refer to panels D and G, respectively. Asterisk in C shows an
area of necrosis, and asterisk in D shows a large tumor cell with marked nuclear atypia
(anaplasia). Horizontal arrows in D and E show prominent nuclear molding. Arrowheads in
D, G and H show mitotic figures. Vertical arrows in E and H show normal granule neurons
in the internal granule layer (igl); the majority of tumor cells in E are much larger than these
cells, whereas those in H are approximately the same size. See also Figure S3.
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Figure 4. MP tumors exhibit characteristics of human MB
Cryosections from MP tumors were stained with H&E (A) or with antibodies specific for
Ki67 (B), Nestin (C), Tuj1 (D), GFAP (E) or BAF47/Ini1 (F). Panels A–E represent
adjacent sections. Scale bars = 50 μm. See also Figure S4.
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Figure 5. Myc is required for continued growth of MP tumors
(A) Strategy for generating Tet-regulatable MP tumors. (B–F) Bioluminescent imaging of
animals at 1, 2 and 3 weeks after tumor cells transplantation. Panel B shows representative
images of 4 animals from each group at each time point (X’s denote animals that died before
they could be imaged). Graphs on right show mean percent increase in bioluminescence for
all animals in the group (with the 1-week signal for each animal set at 100%). In the top
graph, the 1- and 2-week time points represent the average signal intensity for all 14
animals; the 3-week time point (marked by asterisk) represents the average for the 3 animals
that remained alive at the time of imaging. (C–E) H&E-stained cerebellar sections from
representative animals in Groups 1 (C), 2 (D) and 3 (E) three weeks after transplantation.
Arrows in D and E point to injection site. Scale bars = 250 μm. (F) Survival curve (Groups 1
and 2, n=14; Group 3, n=12).
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Figure 6. MP tumors resemble human MYC-driven MB
A, Gene expression profiles of Myc/DNp53 tumors from Prom1+/Lin− cells (MP-pl2-6) or
from Prom1+ cells (MP-P3-7) and Ptch1 mutant (Ptc1-4) tumors were compared to
signatures generated from human MB subtypes: WNT (blue), SHH (red), and Group C/D
(green). Each murine tumor was assigned a score denoting its similarity to each subtype of
human tumor (for details see Human Tumor Analysis Supplement and Table S1). (B–G)
Ptch1 and MP tumors were stained with antibodies specific for secreted frizzled-related
protein 1 (SFRP1, a marker for SHH tumors), Natriuretic Peptide Receptor C (NPR3, a
marker for Group C tumors), or Potassium voltage-gated channel, shaker-related subfamily,
member 1 (KCNA1, a marker for Group D tumors). Scale bars = 100 μm. See also Figure
S5 and Table S1.
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Figure 7. MP tumors are molecularly distinct from stem cells and from Ptch1 tumors
(A) Principle components analysis (PCA). Three PCA coordinates describe 55.2% of total
data variation (PC1 – 27.2%, PC2 – 19.8% and PC3 – 8.23%). Green, MP tumors derived
from Prom1+Lin− cells; purple, MP tumors derived from Prom1+ cells; blue, Ptch1 tumors;
red, normal stem cells (NSCs). (B) Unsupervised hierarchical clustering analysis. Each
column represents a distinct sample and each row represents an individual gene. The
normalized (log2) and standardized (each sample to mean signal = 0 and standard deviation
= 1) level of gene expression is denoted by color (green = low, dark = intermediate, red =
high) as indicated in the gradient at the bottom. (C–F) Genes differentially expressed
between MP tumors and Ptch1 tumors were subjected to NextBio analysis, to identify
Biogroups and Studies that contain similar genes. Representative Biogroups (C–D, E) and
Studies (F) are shown. Venn diagrams show the number of common and unique genes in
both sets. Bars on the right show the significance of overlap between gene subsets (the scale
of the bar is measured in −log(p-value), so taller the bar, the higher the significance of the
gene overlap). Whereas each Biogroup is represented by a single list of genes, signature
genes from Studies have two lists, one for up-regulated and one for down-regulated genes.
Thus, Biogroup comparisons consist of just two graphs, whereas comparisons to Studies
consist of four graphs. See also Tables S2–6.
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Figure 8. Growth of MP tumor cells is inhibited by antagonists of PI3K/mTOR signaling
(A) Effects of inhibitors on short-term proliferation. MP tumor cells were cultured in serum-
free media containing no additive (ø), vehicle (DMSO), cyclopamine (0.1, 1, 2.5 μM),
10058-F4 (10, 25, 100 μM), BEZ-235 (0.2, 1, 5 μM), BKM-120 (0.2, 1, 5μM), or RAD-001
(0.2, 1, 5μM). For each inhibitor, columns are ordered from lowest to highest concentration.
After 48h, cells were pulsed with 3H-Td and cultured overnight before being assayed for 3H-
Td incorporation. Data represent means of triplicate samples ± SEM. (B) Effects on long-
term growth. Tumor cells were cultured for 3, 7 or 14 days in the presence of different doses
of inhibitors and cell number was counted at the indicated time points. (C) Effects on PI3K
signaling. Tumor cells were treated with DMSO, BEZ-235 (5uM, 1uM), BKM-120 (5uM,
1uM), RAD-001(5uM, 1uM) or cyclopamine (2.5uM, 1uM) for 3 hr. Cells were lysed and
protein was analyzed for phosphorylation of AKT and S6 (pAKT and pS6) or for GAPDH
by Western blotting. (D) Effects on tumor growth in vivo. 500 MP tumor cells were re-
transplanted into naïve NSG mice. After 7 days, mice were imaged for luciferase activity
and separated into two groups randomly. Mice in Group 1 were treated with vehicle (0.5%
methyl-cellulose) and those in Group 2 were treated with BKM-120 (30mg/kg per day) by
oral gavage until they developed symptoms. BMK-120 treatment significantly prolonged
survival compared to vehicle (p=0.001). See also Figure S6.
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